Brought to you by 
Sonus Pharmaceuticals terminates Synt:em buy
29 Sep 2020
Executive Summary
To broaden the therapeutic focus of its development pipeline and enhance its discovery capabilities, oncology drug delivery company Sonus Pharmaceuticals is buying private French biotech Synt:em SA (peptide-based CNS therapeutics discovery) in an all-stock transaction.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Bioinformatics
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sonus Pharmaceuticals terminates Synt:em buy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice